Evidence map›Paper›PMID 25538194›Full record

ArticlemBio2014

ADP-ribosylation of NLRP3 by Mycoplasma pneumoniae CARDS toxin regulates inflammasome activity.

Santanu Bose, Jesus A Segovia, Sudha R Somarajan, Te-Hung Chang, T R Kannan, Joel B Baseman

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Living Microbial Drugs.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Molecular mechanisms of NLRP3 inflammasome activation.Experimental & molecular medicine · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Prediction models for refractoryFrontiers in pediatrics · 2026
    Article
  13. Immune dysregulation inFrontiers in immunology · 2026
    Review
  14. Review
  15. Microorganisms · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Santanu BoseDepartment of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA sbose@vetmed.wsu.edu kannan@uthscsa.edu.
Jesus A SegoviaDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Sudha R SomarajanDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Te-Hung ChangDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
T R KannanDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA sbose@vetmed.wsu.edu kannan@uthscsa.edu.
Joel B BasemanDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
The University of Texas Health Science Center at San Antonio · USWashington State University · US

Funding

The role of CARDS toxin in genesis and exacerbation of allergic inflammationU19AI070412 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BASEMAN, JOEL BARRY · 2006 to 2015
$19.7M
Molecular and cellular mechanism regulating innate immunity and inflammation during pattern recognition receptor activation and respiratory virus infectionR01AI083387 · NIAID · WASHINGTON STATE UNIVERSITY · PI BOSE, SANTANU · 2010 to 2021
$3.1M
MOLECULAR MECHANISMS OF MICROBIAL PATHOGENICITYT32AI007271 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ZHONG, GUANGMING · 1985 to 2013
$1.0M
NIAID NIH HHS 5T32AI007271NIAID NIH HHS AI083387NIAID NIH HHS R01 AI083387NIAID NIH HHS T32 AI007271NIAID NIH HHS U19 AI070412NIAID NIH HHS U19AI070412
6 · The paper itself

Abstract

unlabelledThe inflammasome is a major regulator of inflammation through its activation of procaspase-1, which cleaves prointerleukin-1β (pro-IL-1β) into its mature form. IL-1β is a critical proinflammatory cytokine that dictates the severity of inflammation associated with a wide spectrum of inflammatory diseases. NLRP3 is a key component of the inflammasome complex, and multiple signals and stimuli trigger formation of the NLRP3 inflammasome complex. In the current study, we uncovered a yet unknown mechanism of NLRP3 inflammasome activation by a pathogen-derived factor. We show that the unique bacterial ADP-ribosylating and vacuolating toxin produced by Mycoplasma pneumoniae and designated community-acquired respiratory distress syndrome (CARDS) toxin activates the NLRP3 inflammasome by colocalizing with the NLRP3 inflammasome and catalyzing the ADP-ribosylation of NLRP3. Mutant full-length CARDS toxin lacking ADP-ribosyltransferase (ADPRT) activity and truncated CARDS toxins unable to bind to macrophages and be internalized failed to activate the NLRP3 inflammasome. These studies demonstrate that CARDS toxin-mediated ADP-ribosylation constitutes an important posttranslational modification of NLRP3, that ADPRT activity of CARDS toxin is essential for NLRP3 inflammasome activation, and that posttranslational ADPRT-mediated modification of the inflammasome is a newly discovered mechanism for inflammasome activation with subsequent release of IL-1β and associated pathologies. IMPORTANCE: Inflammation is a fundamental innate immune response to environmental factors, including infections. The inflammasome represents a multiprotein complex that regulates inflammation via its ability to activate specific proinflammatory cytokines, resulting in an effective host protective response. However, excessive release of proinflammatory cytokines can occur following infection that skews the host response to "hyperinflammation" with exaggerated tissue damage. Mycoplasma pneumoniae, a common bacterial airway pathogen, possesses a unique protein toxin with ADP-ribosyltransferase and vacuolating properties capable of reproducing the robust inflammation and cytopathology associated with mycoplasma infection. Here, we show that the toxin uniquely activates the NLRP3 inflammasome by colocalizing with and ADP-ribosylating NLRP3, possibly leading to "hyperinflammation" and thus uncovering a novel target for therapeutic intervention.

Indexed as

Host-Pathogen InteractionsProtein Processing, Post-TranslationalAdenosine DiphosphateAnimalsBacterial ProteinsBacterial ToxinsCarrier ProteinsCells, CulturedHumansInflammasomesMacrophagesMiceMycoplasma pneumoniaeNLR Family, Pyrin Domain-Containing 3 ProteinAdenosine DiphosphateBacterial ProteinsBacterial ToxinsCARDS toxin, Mycoplasma pneumoniaeCarrier ProteinsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, human

Identifiers

PMID25538194
PMCPMC4278538
OpenAlexW2102428625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.